Related Experiment Video

Updated: Dec 12, 2025

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

4.3K

Longitudinal changes of liver function and hepatitis B reactivation in COVID-19 patients with pre-existing chronic

Jiaye Liu1, Tingyan Wang2, Qingxian Cai1

  • 1National Clinical Research Center for Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China.

Hepatology Research : the Official Journal of the Japan Society of Hepatology
|August 8, 2020
PubMed

Insights

COVID-19 patients with chronic hepatitis B virus (HBV) infection showed similar liver function changes to those without HBV. However, co-infected patients face a risk of hepatitis B reactivation, necessitating monitoring of liver function and HBV-DNA levels.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Virology

Background:

  • The COVID-19 pandemic and high prevalence of chronic Hepatitis B Virus (HBV) infection globally necessitate understanding their interactions.
  • Investigating the impact of SARS-CoV-2 on chronic HBV infection and liver function is crucial.

Purpose of the Study:

  • To compare liver function changes in COVID-19 patients with and without chronic HBV infection.
  • To assess the risk of hepatitis B reactivation in COVID-19 patients co-infected with HBV.

Main Methods:

  • Retrospective study of 347 COVID-19 patients, comparing 21 with chronic HBV to 326 without.
  • Propensity score matching (PSM) created comparable groups of 20 HBV patients and 51 non-HBV patients.
  • Longitudinal monitoring of liver biochemistries and SARS-CoV-2 clearance.

Main Results:

  • No significant differences in liver biochemistries (ALT, AST, GGT, total bilirubin) between HBV and non-HBV groups post-PSM.
  • Similar rates of progression to severe COVID-19 in both groups (30% vs. 31.4%).
  • Three patients (15%) in the HBV group experienced hepatitis B reactivation.

Conclusions:

  • COVID-19 patients with or without chronic HBV exhibit comparable liver dysfunction.
  • Chronic HBV co-infection poses a risk for hepatitis B reactivation during COVID-19.
  • Continuous monitoring of liver function and HBV-DNA is essential for co-infected patients.
Abstract

Keywords:
COVID-19HBVhepatitis B reactivationliver function

More Related Videos

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

11.9K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.2K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
106
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.7K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
133
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
106
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
122